5 Things to Know Before the Stock Market Opens on Thursday

Stock futures are slightly higher as investors weigh Middle East developments. PepsiCo posted a narrow earnings beat, with international strength offsetting sluggish North America sales, but AstraZeneca shares are falling after a disappointing heart-drug trial and Levi Strauss is dropping on weak guidance. SK Hynix is also reportedly seeing heavy demand ahead of its upcoming U.S. stock listing.

Analysis

This reads like a dispersion tape, not a macro impulse: the market is rewarding defensiveness with non-U.S. revenue and punishing companies that depend on cleaner demand visibility in the U.S. For PEP, the important mechanism is that international mix can mask domestic volume weakness for a while, but if North American softness persists it usually shows up later through heavier promotions, package shrink, and slower operating leverage — so the stock may be a better relative long than an outright earnings momentum story.

LEVI looks more like a channel signal than a single-name problem. Weak forward commentary in apparel typically means retailers are still clearing inventory and consumers are trading down, which tends to pressure full-price mall names before it helps off-price. The second-order winner is usually TJX/ROST, while the loser set expands to any discretionary names that rely on fresh fashion cycles and low markdowns.

AZN’s trial miss is only structurally bearish if the asset was carrying a meaningful share of medium-term growth expectations; otherwise the stock can stabilize once analysts haircut probability-weighted forecasts. The Middle East backdrop is a short-horizon volatility risk for broad equities, but unless oil moves materially it’s more about intraday positioning than a durable regime change. The SK Hynix listing interest is a sentiment tell for AI memory, but without pricing/float data it is an alert, not yet a tradable edge.

Key Decisions for Investors

• Long PEP / short KHC or GIS on any post-print strength: PEP’s international mix deserves a premium versus more U.S.-centric packaged-food peers; target a 3-6 month relative outperformance trade, but cut if U.S. volumes deteriorate further or gross margin guidance rolls over.
• Short LEVI vs long TJX or ROST into the next 1-2 quarters: weak apparel guidance tends to mean more markdown pressure across specialty retail, while off-price can source inventory cheaply; thesis fails if promotional intensity normalizes and LEVI stops cutting outlook.
• Do not force an AZN outright short today; instead, place it on a watchlist for a rally-fade if sell-side EPS revisions keep drifting lower over the next 2-4 weeks. The trade only works if the market treats the pipeline setback as a multiple event, not a one-off clinical miss.
• Watch SMH/MU into the SK Hynix listing bookbuild; strong pricing or aftermarket performance would support the AI-memory complex over the next 1-3 months, but absent valuation details this is confirmation-risk, not a standalone position.